Literature DB >> 16123480

Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis.

Carlos E Milla1, Joanne Billings, Antoinette Moran.   

Abstract

OBJECTIVE: Survival analysis was performed on a prospectively followed cohort of patients with cystic fibrosis (CF) to determine the impact of the development of diabetes on survival. RESEARCH DESIGN AND METHODS: Clinical data were retrieved for patients diagnosed with CF-related diabetes (CFRD) at the Minnesota CF Center in 1987-2002. Kaplan-Meier survival analysis was performed to estimate median survival. Data were analyzed by Cox regression to evaluate the influence of clinical characteristics at the time of CFRD diagnosis on mortality.
RESULTS: Clinical information was reviewed from 1,081 CF patients. A total of 123 patients with CFRD with fasting hyperglycemia were identified (58 males). Median survival was 49.5 years for male subjects without diabetes, 47.4 years for male subjects with diabetes, 47.0 years for female subjects without diabetes, and 30.7 years for female subjects with diabetes. Only female sex and forced expiratory volume in 1 s at the time of CFRD diagnosis were significant predictors of the subsequent risk of death (P < 0.001). This strong association was not confounded by CFTR genotype, BMI, steroid use, respiratory pathogens, HbA1c, or pregnancy.
CONCLUSIONS: Female subjects with CFRD have a remarkably poorer prognosis compared with all male subjects with CF and female subjects with CF but without diabetes. The etiology of this sex difference is not clear. We speculate it might involve the interaction of female hormones and diabetes on promotion of a proinflammatory state or that androgens might protect male subjects from the catabolic effects of insulin deficiency. Alternatively, the appearance of frank diabetes in female subjects with CF may simply be a marker for some other biological difference that is not immediately apparent.

Entities:  

Mesh:

Year:  2005        PMID: 16123480     DOI: 10.2337/diacare.28.9.2141

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  45 in total

Review 1.  Routine screening for cystic fibrosis-related diabetes.

Authors:  Daniel Peckham
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

2.  Cystic fibrosis-related diabetes in adults: where can we go from here?

Authors:  Harold W de Valk; Eduard A van der Graaf
Journal:  Rev Diabet Stud       Date:  2007-05-10

3.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

4.  Sex disparities in effects of cystic fibrosis-related diabetes on clinical outcomes: a matched study.

Authors:  R J Miller; H D Tildesley; P G Wilcox; H Zhang; S H Kreisman
Journal:  Can Respir J       Date:  2008-09       Impact factor: 2.409

5.  Cystic fibrosis-related diabetes in adults: inpatient management of 121 patients during 410 admissions.

Authors:  Neda Rasouli; Stacey Seggelke; Joanna Gibbs; R Matthew Hawkins; Matthew L Casciano; Elizabeth Cohlmia; Jennifer Taylor-Cousar; Cecilia Wang; Rocio Pereira; Elisa Hsia; Boris Draznin
Journal:  J Diabetes Sci Technol       Date:  2012-09-01

6.  Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial.

Authors:  Antoinette Moran; Penelope Pekow; Patricia Grover; Martha Zorn; Bonnie Slovis; Joseph Pilewski; Elizabeth Tullis; Theodore G Liou; Holley Allen
Journal:  Diabetes Care       Date:  2009-07-10       Impact factor: 17.152

7.  HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression.

Authors:  Douglas Conrad; Angela Wang; Raymond Pieters; Ferdinando Nicoletti; Katia Mangano; Anna M van Heeckeren; Steven K White; James M Frincke; Christopher L Reading; Dwight Stickney; Dominick L Auci
Journal:  J Inflamm (Lond)       Date:  2010-10-30       Impact factor: 4.981

8.  Impaired fasting glucose in cystic fibrosis.

Authors:  Brigitte I Frohnert; Katie Larson Ode; Antoinette Moran; Brandon M Nathan; Theresa Laguna; Bonnie Holme; William Thomas
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

Review 9.  Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.

Authors:  Antoinette Moran; Dorothy Becker; Samuel J Casella; Peter A Gottlieb; M Sue Kirkman; Bruce C Marshall; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

10.  Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality.

Authors:  Antoinette Moran; Jordan Dunitz; Brandon Nathan; Asad Saeed; Bonnie Holme; William Thomas
Journal:  Diabetes Care       Date:  2009-06-19       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.